ASCO GU 2018: Clinical Data for Atezolizumab + Avastin in Renal Cell Carcinoma

At the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2018) held in San Francisco, California, Dr. Robert J. Motzer from Memorial Sloan Kettering Cancer Center presented the results of the IMmotion151 Phase 3 clinical trial (NCT02420821).

IMmotion151 Trial: Atezolizumab + Bevacizumab vs. Sunitinib

The study involved 915 patients with untreated metastatic renal cell carcinoma (mRCC). Participants were randomized 1:1 into two groups:

1. Group A: Atezolizumab 1,200 mg + Bevacizumab (Avastin) 15 mg/kg every three weeks.
2. Group B: Sunitinib 50 mg daily for four weeks, followed by a one-week rest.

The primary objective was to compare progression-free survival (PFS) in patients with PD-L1 expression (≥1%).

Key Findings (Median Follow-up of 15 Months)

Progression-Free Survival (PFS) in PD-L1+ Patients

• Group A (Atezolizumab + Avastin): 11.2 months
• Group B (Sunitinib): 7.7 months
• The combination therapy demonstrated a 26% reduction in the risk of disease progression or death compared to Sunitinib.

Overall Survival (OS)

Statistical analysis for OS is ongoing, as current data reached insufficient maturity for a definitive conclusion at the time of this report.

Safety and Adverse Events (TRAE)

• Treatment-Related Adverse Events (TRAE): 40% in Group A vs. 54% in Group B.
• Discontinuation due to TRAEs: 12% in Group A vs. 8% in Group B.

Conclusion

Dr. Robert J. Motzer emphasized that for metastatic renal cell carcinoma patients—whose five-year survival rate is currently less than 20%—the combination of Atezolizumab and Avastin extends median PFS by 3.5 months. This combination therapy represents a significant new treatment option for patients with metastatic RCC.

#RenalCellCarcinoma #Atezolizumab #Avastin #Immunotherapy #CancerResearch

Figure 1

Figure 2

Figure 3

Figure 4